Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine + oxybutynin for Japanese patients with obstructive sleep apnea
jRCTs031200046Completed
- Sponsor
- Chiba University Hospital
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of atomoxetine and oxybutynin in obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Chiba University Hospital. Primary endpoint: Apnea–hypopnea index (AHI) change. Started Jun 2020; status: completed.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on jRCTs031200046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200046.